Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

10.58USD
23 Sep 2016
Change (% chg)

$0.35 (+3.42%)
Prev Close
$10.23
Open
$10.23
Day's High
$10.65
Day's Low
$10.17
Volume
35,072
Avg. Vol
36,154
52-wk High
$10.75
52-wk Low
$3.93

Latest Key Developments (Source: Significant Developments)

Stemline Therapeutics Q2 loss per share $0.52
Thursday, 4 Aug 2016 07:59am EDT 

Stemline Therapeutics Inc : Q2 loss per share $0.52 . Stemline Therapeutics reports second quarter 2016 financial results and highlights recent clinical progress .Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics reports Q1 loss per share $0.51
Monday, 9 May 2016 08:00am EDT 

Stemline Therapeutics Inc : Stemline Therapeutics reports first quarter 2016 financial results . Q1 loss per share $0.51 .Q1 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics Inc announces SL-401 receives EU Orphan Drug designation for treatment of BPDCN
Monday, 2 Nov 2015 08:01am EST 

Stemline Therapeutics Inc:Says European Medicines Agency has granted Orphan Drug designation to SL-401 for the treatment of blastic plasmacytoid dendritic cell neoplasm.Stemline is evaluating SL-401 in multiple clinical programs, including an ongoing pivotal trial in BPDCN as well as trials in additional hematological cancers.  Full Article

Stemline Therapeutics Inc announces SL-401 receives eu orphan drug designation for treatment of acute myeloid leukemia
Thursday, 10 Sep 2015 08:00am EDT 

Stemline Therapeutics Inc:Announces SL-401 receives EU orphan drug designation for treatment of acute myeloid leukemia (AML).Says is evaluating SL-401 in three trials across 7 different indications.  Full Article

Stemline Therapeutics announces SL-701 receives orphan drug designation for the treatment of Glioma
Friday, 30 Jan 2015 08:30am EST 

Stemline Therapeutics Inc:Says SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.SL-701 is an enhanced immunotherapy designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that arise in both adults and children.  Full Article

Stemline Therapeutics prices $59.85 million public offering of common stock
Thursday, 8 Jan 2015 09:05am EST 

Stemline Therapeutics Inc:Says the pricing of underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.75 per share.Also granted underwriters a 30-day option to purchase up to an additional 570,000 shares of common stock from Stemline.Gross proceeds to Stemline from the public offering are expected to be $59.85 mln, before deducting estimated underwriting discounts and commissions and other estimated offering expenses.Offering is expected to close on Jan. 13.Intends to use the net proceeds to fund the clinical development of SL-401, SL-701, the development of its preclinical pipeline, and other general corporate purposes.Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.Aegis Capital Corp is acting as co-lead manager for the offering.Roth Capital Partners, Ladenburg Thalmann and H.C. Wainwright & Co. are acting as co-managers for the offering.  Full Article

Stemline Therapeutics Inc announces proposed public offering of common stock
Wednesday, 7 Jan 2015 04:01pm EST 

Stemline Therapeutics Inc:Intends to offer and sell shares of common stock in underwritten public offering.Expects to grant the underwriters 30-day option to purchase up to additional 15 pct of shares of common stock offered in offering.Intends to use the net proceeds from public offering to fund the clinical development of SL-401, SL-701, the development of preclinical pipeline and other general corporate purposes.Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for offering.Aegis Capital Corp is acting as co-lead manager for the offering.Proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

CanBas signs license agreement with Stemline Therapeutics
Friday, 26 Dec 2014 01:50am EST 

CanBas Co Ltd:Signed a license agreement on development of anti-cancer agent candidate compound CBS9106 with Stemline Therapeutics.To provide exclusive right of development, manufacture and commercialization of CBS9106 in the world (except China, Taiwan and Korea) to Stemline Therapeutics.  Full Article

Stemline Therapeutics initiates SL-401 trial in AML Patients in first complete response with Minimal Residual Disease
Thursday, 16 Oct 2014 07:00am EDT 

Stemline Therapeutics Inc:Say initiates SL-401 Trial in AML patients in first complete response with Minimal Residual Disease, the second SL-401 trial initiated in 2H14.Says initiation of its second clinical trial for SL-401, targeted therapy directed to interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of wide range of hematologic cancers.This trial will enroll patients with acute myeloid leukemia (AML) who have achieved complete response (CR) following their first course of induction chemotherapy, but display evidence of minimal residual disease (MRD) in their bone marrow and are at high risk for relapse.The study is designed to enroll at least 33 patients and will include brief lead-in that will transition into larger expansion stage.The trial will evaluate, among other parameters, SL-401's ability to eradicate evidence of MRD and increase CR duration.Participating sites include MD Anderson Cancer Center (Houston, TX), Duke University Medical Center (Durham, NC), and other centers.This trial follows first trial of SL-401, which is in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed/refractory AML and is actively accruing patients.  Full Article

BRIEF-Stemline Therapeutics expect to provide further updates around multiple SL-401

* Receives Breakthrough Therapy Designation From U.S. Food And Drug Administration For SL-401